Postural tachycardia syndrome (POTS) and antiphospholipid syndrome (APS) : What do we know so far?

被引:3
作者
Noureldine, H. A. [1 ]
El Hasbani, G. [2 ]
Eldine, M. Nour [1 ]
Nour-Eldine, W. [3 ]
Taher, A. [4 ]
Uthman, I [2 ]
机构
[1] Lebanese Amer Univ, Gilbert & Rose Marie Chagoury Sch Med, Byblos, Lebanon
[2] Amer Univ Beirut, Dept Internal Med, Med Ctr, Beirut, Lebanon
[3] Hamad Bin Khalifa Univ, Qatar Fdn, Neurol Disorders Res Ctr, Qatar Biomed Res Inst, Doha, Qatar
[4] Amer Univ Beirut, Dept Internal Med, Div Hematol & Med Oncol, Med Ctr, Beirut, Lebanon
关键词
Antiphospholipid syndrome; Postural orthostatic tachycardia    syndrome; Autonomic dysfunction; Antiphospholipid antibodies; Cytokines; Anticoagulation; INTERNATIONAL CONSENSUS STATEMENT; SYSTEMIC-LUPUS-ERYTHEMATOSUS; AUTONOMIC DYSFUNCTION; HUGHES-SYNDROME; DERMATOLOGICAL MANIFESTATIONS; ANTICARDIOLIPIN ANTIBODIES; CLASSIFICATION CRITERIA; ANGIOTENSIN-II; C1Q RECEPTORS; NEUROPATHY;
D O I
10.1016/j.neurol.2021.10.006
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
As part of the non-criteria clinical manifestations, postural orthostatic tachycardia syndrome (POTS), a multisystem autonomic dysfunction, can co-exist with antiphospholipid syndrome (APS). Several pieces of evidence hint on the autoimmune basis of POTS, and its possible association with several autoimmune diseases, including APS. Indeed, the evidence exists in the etiologies, symptomatology, and treatment options. Although infections, viral ones in particular, stress, and pregnancy are etiologies to both POTS and APS, the exact pathophysiological connection is still to be studied taking into consideration the activity of cytokines in both diseases. Nevertheless, certain immunomodulatory treatments used for the catastrophic or obstetrical forms of APS, such as intravenous immunoglobulins (IVIG) and steroids, have been also used for the treatment of POTS resistant to classical treatments. Therefore, our review aims to highlight the association between POTS and APS, shedding light on the common etiologies explaining the pathophysiology of the two disorders, the diagnostic approach to POTS as a possible clinical criterion of APS, and the treatment of APS in the context of treating POTS. (c) 2021 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:306 / 314
页数:9
相关论文
共 37 条
  • [11] The antiphospholipid syndrome: What are we really measuring? How do we measure it? And how do we treat it?
    Ortel, TL
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2006, 21 (01) : 79 - 83
  • [12] Postural Orthostatic Tachycardia Syndrome (POTS) and Vitamin B12 Deficiency in Adolescents
    Oner, Taliha
    Guven, Baris
    Tavli, Vedide
    Mese, Timur
    Yilmazer, Murat Muhtar
    Demirpence, Savas
    PEDIATRICS, 2014, 133 (01) : E138 - E142
  • [13] Malmo POTS symptom score: Assessing symptom burden in postural orthostatic tachycardia syndrome
    Spahic, Jasmina Medic
    Hamrefors, Viktor
    Johansson, Madeleine
    Ricci, Fabrizio
    Melander, Olle
    Sutton, Richard
    Fedorowski, Artur
    JOURNAL OF INTERNAL MEDICINE, 2023, 293 (01) : 91 - 99
  • [14] The patient perspective: What postural orthostatic tachycardia syndrome patients want physicians to know
    Stiles, Lauren E.
    Cinnamon, Jaclyn
    Balan, Irina
    AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL, 2018, 215 : 121 - 125
  • [15] Disease mechanisms in Sjogren's syndrome: What do we know?
    Jonsson, Roland
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2022, 95 (03)
  • [16] Reduced cardiovagal baroreflex sensitivity is associated with postural orthostatic tachycardia syndrome (POTS) and pain chronification in patients with headache
    Mueller, Bridget R.
    Ray, Carly
    Benitez, Alyha
    Robinson-Papp, Jessica
    FRONTIERS IN HUMAN NEUROSCIENCE, 2023, 17
  • [17] Diagnosis and management of obstetrical antiphospholipid syndrome: where do we stand?
    Marchetti, Tess
    Cohen, Marie
    Gris, Jean-Christophe
    de Moerloose, Philippe
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2013, 123 (12): : 1 - 7
  • [18] Role of platelet factor 4 in arteriovenous fistula maturation failure: What do we know so far?
    Xiao, Yuxuan
    Vazquez-Padron, Roberto, I
    Martinez, Laisel
    Singer, Harold A.
    Woltmann, Daniel
    Salman, Loay H.
    JOURNAL OF VASCULAR ACCESS, 2024, 25 (02) : 390 - 406
  • [19] Genomic and rapid effects of aldosterone: what we know and do not know thus far
    Hermidorff, Milla Marques
    Monteiro de Assis, Leonardo Vinicius
    Isoldi, Mauro Cesar
    HEART FAILURE REVIEWS, 2017, 22 (01) : 65 - 89
  • [20] Soluble Factors and Receptors Involved in Skin Innate Immunity-What Do We Know So Far?
    Scurtu, Lucian G.
    Simionescu, Olga
    BIOMEDICINES, 2021, 9 (12)